Latest filing published 05 Nov 2026 for Lyell Immunopharma, Inc., €22.2M.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -42.0%Entry US$25.63 · Close 06 Nov 2026 US$14.86
- +153.9%Entry US$14.41 · Close at T+365 US$36.59
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
ARCH Venture Partners IX, LLC: trading record in brief
ARCH Venture Partners IX, LLC discloses dealings in 5 companies, chiefly Vir Biotechnology, Inc., Beam Therapeutics Inc. and Karuna Therapeutics, Inc. In total, 153 filings cover trades dated from 12 February 2019 to 4 November 2026.
Purchases make up the whole of the open-market record (5 purchases, €53.9M). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2026 alone, the filings show 2 purchases and no sales.
A typical purchase (the median) is worth €10.8M. On 4 out of 4 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.
The record was last updated on 5 November 2026 with an open-market purchase (€22.2M) in Lyell Immunopharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to ARCH Venture Partners IX, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,321,262 shares@ US$10.779.47% mcap67.3% of flowCommon StockSEC:0001012975-26-001014:0Canonical exit: 2 Feb 2027 (T+90)
- 488,090 shares@ US$25.61100.0% of flowCommon StockSEC:0001012975-26-000235:0Canonical exit: 4 Jun 2026 (T+90)
- 196,003 shares0Common StockSEC:0001062993-22-019342:0
- 253,997 shares0Common StockSEC:0001062993-22-019342:1
- 11,763 shares0Common StockSEC:0001062993-22-019342:2
- 1,338 shares0Common StockSEC:0001062993-22-019342:3
- 2,662 shares0Common StockSEC:0001062993-22-019342:4
- 239,559 shares0Common StockSEC:0001062993-22-019342:5
- 310,441 shares0Common StockSEC:0001062993-22-019342:6
- 14,383 shares0Common StockSEC:0001062993-22-019342:7
- 1,624 shares0Common StockSEC:0001062993-22-019342:8
- 3,248 shares0Common StockSEC:0001062993-22-019342:9
- 282,219 shares0Common StockSEC:0001062993-22-018984:1
- 13,076 shares0Common StockSEC:0001062993-22-018984:2
- 1,475 shares0Common StockSEC:0001062993-22-018984:3
- 2,952 shares0Common StockSEC:0001062993-22-018984:4
- 217,781 shares0Common StockSEC:0001062993-22-018984:5
- 282,219 shares0Common StockSEC:0001062993-22-018984:6
- 13,076 shares0Common StockSEC:0001062993-22-018984:7
- 1,475 shares0Common StockSEC:0001062993-22-018984:8
- 2,952 shares0Common StockSEC:0001062993-22-018984:9
- 217,781 shares0Common StockSEC:0001062993-22-018984:0
- 282,219 shares0Common StockSEC:0001062993-22-018811:1
- 13,076 shares0Common StockSEC:0001062993-22-018811:2
- 1,475 shares0Common StockSEC:0001062993-22-018811:3
25 of 152 declarations
